Tokyo Cell Clinic, the first medical institution exported by CHA Medical Group to Japan, is located in New Pier Takeshiba South Tower, Tokyo and specializes in immunocyte treatment. Tokyo Cell Clinic was founded to help people suffering from diseases caused by a weakened immune system (e.g. using immunocyte therapy (AKC immunotherapy) to treat cancer).

Tokyo Cell Clinic has state-of-the-art cell processing facilities complying with good manufacturing practices (GMP) for high quality cell processing, which is most important in immunocyte therapy. Its advanced facilities separate and culture cells as soon as a patient’s blood is collected. Tokyo Cell Clinic manages cell quality hygienically and complies with International standards, so that everyone who receives treatment will have peace of mind.HOMEPAGE

CHA Hollywood Presbyterian Medical Center, acquired by CHA Health Systems in 2004, is the first general hospital in the U.S. owned and operated by a Korean company. It is an exemplary case of globalization for the Korean medical business. CHA Hollywood Presbyterian Medical Center is composed of seven buildings with a total surface area of 30,000-pyeong (356 Thousand Square feet), approximately 600 medical professionals and 1,500 employees.HOMEPAGE

After 20-years of effort to create stable ‘human egg freezing technology,’ CHA Medical Group hasfinally developed the world’s first ‘oocyte cryopreservation by vitrification’ in 1998. In 2005, CHAMedical Group developed ‘oocyte cryopreservation using slush nitrogen’ which improved thesurvival rate to 90%. Due to its advanced medical technologies, CHA group has been globallyrecognized for its technical expertise and efficiency.

CHA Fertility Center Los Angeles set a new precedent by shifting the paradigm of Koreanmedicine, which was limited to Korean medical circles to expansion into foreign medicalmarkets. It was recognized by local media as a splendid achievement that demonstratedthe promise of Korean medicine. HOMEPAGE

CHA Medical Group, recognized as a world class authority in global medicalcircles with its state-of-the-art technology for infertility treatment,opened Cha-Columbia Fertility Center in association with ColumbiaUniversity’s Department of Obstetrics and Gynecology in May 1999.

This remarkable achievement was realized thanks to CHA Medical Group’sresearch infrastructure, advanced research, and outstanding technology.It remains a case example of successfully exporting Korean medicaltechnology to the U.S., a nation at the forefront of advanced medicine.Chairman Kwang-yul Cha served as an exchange professor for ColumbiaUniversity’s Department of Obstetrics and Gynecology.